Many small / macro molecule-based STING pathway modulators are currently being evaluated as monotherapies as well as in combination with other drugs, claims Roots Analysis
In recent years, the concept of STING pathway targetingtherapeutics has generated a lot of enthusiasm within the medical sciencecommunity. The growing popularity of this therapeutic technique has not onlygarnered the interest of several medical researchers (reflected in theincreasing volume of scientific literature (1,000+ articles published since2015) on this subject), but also industry stakeholders focused on drugdevelopment (evident in the growing number of clinical trials and the grantsawarded for STING focused projects in the recent past).
To order this 310+page report, which features 170+ figures and 200+ tables, please visit this link
The USD 2.8 billion (by 2030)financial opportunity within the STING pathway targeting technologies markethas been analysed across the following segments:
§ Types of Payment
§ Upfront Payments
§ Milestone Payments
§ Type of STINGModulator
§ Agonist
§ Antagonist
§ Key TherapeuticArea(s)
§ Oncological Disorders
§ InflammatoryDisorders
§ Infectious Diseases
§ Others
§ Route ofAdministration
§ Intratumoral
§ Intravenous
§ Oral
§ Subcutaneous
§ Others
§ Type of Molecule
§ Non-nucleotide
§ Cyclic Dinucleotide
§ Live Biotherapeutics
§ Oncolytic Peptides
§ Synthetic Peptides
§ Others
§ Key GeographicalRegions
§ North America
§ Europe
§ Asia-Pacific
The STING Pathwaytargeting Therapeutics and Technologies, 2020-2030 report features thefollowing companies, which we identified to be key players in this domain:
§ Aduro Biotech
§ Bristol Myers Squibb
§ Eisai
§ GlaxoSmithKline
§ ImmuneSensor Therapeutics
§ Merck
§ Noxopharm
§ Spring Bank Pharmaceuticals
§ Synlogic
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. STING Pathway Targeting Therapeutics: CurrentMarket Landscape
5. STING Pathway Targeting Technologies: Current Marketlandscape
6. Company Profiles
7. Academic Grant Analysis
8. STING Related Initiatives of Big Pharmaceutical Players
9. Start-up Health Indexing
10. Publication Analysis
11. Partnerships and Collaborations
12. Funding and Investment Analysis
13. Market Sizing and Opportunity Analysis
14. Executive Insights
15. Concluding Remarks
16. Appendix 1: Tabulated Data
17. Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/sting-pathway-targeting-therapeutics-and-technologies-market.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
